Valeant Announces Second-Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant Pharma (VRX) Reports Q2 Loss of $0.11, Adj-EBITDA Beats; Maintains FY EPS, Lowers FY Revs
August 8, 2017 7:06 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of ($0.11), versus ($0.88) reported last year. Revenue for the quarter came in at $2.23 billion, versus $2.42 billion reported last year.
Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 million, beating consensus of $910.8 million.
Second-Quarter 2017 Financial Results
Revenues of $2.233... More